Treatment of enterohemorrhagic escherichia coli -induced hemolytic uremic syndrome (eHUS)

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 4, 2014, Pages 508-516

  Würzner, Reinhard ^a   Riedl, Magdalena ^a,b,c   Rosales, Alejandra ^a   Orth Höller, Dorothea ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

complement; enterohemorrhagic Escherichia coli; hemolytic uremic syndrome; Shiga toxin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COMPLEMENT COMPONENT C5 INHIBITOR; ECULIZUMAB; FOSFOMYCIN; FUROSEMIDE; GENTAMICIN; HEPARIN; IMMUNOGLOBULIN G; PROSTACYCLIN; STEROID; STREPTOKINASE; ANTIINFECTIVE AGENT; COMPLEMENT; COMPLEMENT INHIBITOR;

ACTIVE IMMUNIZATION; ANTIBIOTIC THERAPY; ARTICLE; COMPLEMENT ACTIVATION; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENTEROHEMORRHAGIC ESCHERICHIA COLI INDUCED HEMOLYTIC UREMIC SYNDROME; ENTEROHEMORRHAGIC ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI INFECTION; EXPERIMENTAL THERAPY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOADSORPTION; IN VITRO STUDY; INNATE IMMUNITY; INTENSIVE CARE; LONG TERM CARE; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PASSIVE IMMUNIZATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; TREATMENT RESPONSE; ADSORPTION; EPIDEMIC; ESCHERICHIA COLI INFECTIONS; GERMANY; HEMOLYTIC-UREMIC SYNDROME; MICROBIOLOGY; MUTATION; TREATMENT OUTCOME;

ADSORPTION; ANTI-BACTERIAL AGENTS; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; DISEASE OUTBREAKS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GERMANY; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION; PLASMA EXCHANGE; TREATMENT OUTCOME;

EID: 84902290656     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1375298     Document Type: Article

References (64)

1. Keir L. S., Marks S. D., Kim J. J. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther: 2012; 6 195 208
2. Orth-Höller D., Würzner R. Role of complement in enterohemorrhagic Escherichia coli -induced hemolytic uremic syndrome. Sem Thromb Hemost: 2014; 40 4 503 507
3. Orth D., Würzner R. What makes an enterohemorrhagic Escherichia coli? Clin Infect Dis: 2006; 43 9 1168 1169
4. Jenke C., Lindstedt B. A., Harmsen D., Karch H., Brandal L. T., Mellmann A. Comparison of multilocus variable-number tandem-repeat analysis and multilocus sequence typing for differentiation of hemolytic-uremic syndrome-associated Escherichia coli (HUSEC) collection strains. J Clin Microbiol: 2011; 49 10 3644 3646
5. Geerdink L. M., Westra D., van Wijk J. A., et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol: 2012; 27 8 1283 1291
6. Orth D., Grif K., Zimmerhackl L. B., Würzner R. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev Anti Infect Ther: 2008; 6 1 101 108
7. Friedrich A. W., Bielaszewska M., Zhang W. L., et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis: 2002; 185 1 74 84
8. Orth D., Grif K., Khan A. B., Naim A., Dierich M. P., Würzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis: 2007; 59 3 235 242
9. Melton-Celsa A., Mohawk K., Teel L., O'Brien A. Pathogenesis of Shiga-toxin producing Escherichia coli. Curr Top Microbiol Immunol: 2012; 357 67 103
10. Tarr P. I., Gordon C. A., Chandler W. L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet: 2005; 365 9464 1073 1086
11. Orth-Höller D., Riedl M., Würzner R. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside. EMBO Mol Med: 2011; 3 11 617 619
12. Trachtman H., Austin C., Lewinski M., Stahl R. A. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol: 2012; 8 11 658 669
13. Frank C., Werber D., Cramer J. P., et al. HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med: 2011; 365 19 1771 1780
14. Bitzan M., Poole R., Mehran M., et al. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother: 2009; 53 7 3081 3087
15. Ake J. A., Jelacic S., Ciol M. A., et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics: 2005; 115 6 e673 e680
16. Ikeda K., Ida O., Kimoto K., Takatorige T., Nakanishi N., Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol: 1999; 52 6 357 362
17. Safdar N., Said A., Gangnon R. E., Maki D. G. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA: 2002; 288 8 996 1001
18. Ichinohe N., Ohara-Nemoto Y., Nemoto T. K., Kimura S., Ichinohe S. Effects of fosfomycin on Shiga toxin-producing Escherichia coli: quantification of copy numbers of Shiga toxin-encoding genes and their expression levels using real-time PCR. J Med Microbiol: 2009; 58 Pt 7 971 973
19. Papan C. Effect of antibiotics on Shiga toxin release of EHEC bacteria-is gentamicin the drug of choice. MD thesis Innsbruck Medical University: 2010
20. Grif K., Orth D., Würzner R. In vitro effect of exposure of different antibiotics on EHEC strains with various types of Shiga toxin. VTEC2009. P01.5.8 Abstract Book: 2009; 105
21. Bielaszewska M., Idelevich E. A., Zhang W., et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother: 2012; 56 6 3277 3282
22. Corogeanu D., Willmes R., Wolke M., Plum G., Utermöhlen O., Krönke M. Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak. BMC Microbiol: 2012; 12 160
23. Slutsker L., Ries A. A., Maloney K., Wells J. G., Greene K. D., Griffin P. M. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis: 1998; 177 4 962 966
24. Zhang X., McDaniel A. D., Wolf L. E., Keusch G. T., Waldor M. K., Acheson D. W. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis: 2000; 181 2 664 670
25. Wong C. S., Jelacic S., Habeeb R. L., Watkins S. L., Tarr P. I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med: 2000; 342 26 1930 1936
26. Dundas S., Todd W. T., Stewart A. I., Murdoch P. S., Chaudhuri A. K., Hutchinson S. J. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis: 2001; 33 7 923 931
27. Smith K. E., Wilker P. R., Reiter P. L., Hedican E. B., Bender J. B., Hedberg C. W. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J: 2012; 31 1 37 41
28. Wong C. S., Mooney J. C., Brandt J. R., et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis: 2012; 55 1 33 41
29. Hauswaldt S., Nitschke M., Sayk F., Solbach W., Knobloch J. K. Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli. Curr Infect Dis Rep: 2013; 15 1 4 9
30. Michael M., Elliott E. J., Craig J. C., Ridley G., Hodson E. M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis: 2009; 53 2 259 272
31. Loos S., Ahlenstiel T., Kranz B., et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis: 2012; 55 6 753 759
32. Loirat C., Garnier A., Sellier-Leclerc A. L., Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost: 2010; 36 6 673 681
33. Rizzoni G., Claris-Appiani A., Edefonti A., et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr: 1988; 112 2 284 290
34. Gianviti A., Perna A., Caringella A., et al. Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis: 1993; 22 2 264 266
35. Loirat C., Sonsino E., Hinglais N., Jais J. P., Landais P., Fermanian J.; The French Society of Paediatric Nephrology. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. Pediatr Nephrol: 1988; 2 3 279 285
36. Szczepiorkowski Z. M., Winters J. L., Bandarenko N., et al. Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher: 2010; 25 3 83 177
37. Colic E., Dieperink H., Titlestad K., Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet: 2011; 378 9796 1089 1093
38. Greinacher A., Friesecke S., Abel P., et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet: 2011; 378 9797 1166 1173
39. Menne J., Nitschke M., Stingele R., et al. EHEC-HUS consortium. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ: 2012; 345 e4565
40. Rosales A., Hofer J., Zimmerhackl L. B., et al. German-Austrian HUS Study Group. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis: 2012; 54 10 1413 1421
41. Orth D., Khan A. B., Naim A., et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol: 2009; 182 10 6394 6400
42. Lapeyraque A. L., Malina M., Fremeaux-Bacchi V., et al. Eculizumab in severe Shiga toxin associated HUS. N Engl J Med: 2011; 364 26 2561 2563
43. Hillmen P., Muus P., Röth A., et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol: 2013; 162 1 62 73
44. Legendre C. M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med: 2013; 368 23 2169 2181
45. Würzner R., Schulze M., Happe L., et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm: 1991; 8 5-6 328 340
46. Evans M. J., Rollins S. A., Wolff D. W., et al. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol: 1995; 32 16 1183 1195
47. Rother R. P., Rollins S. A., Mojcik C. F., Brodsky R. A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol: 2007; 25 11 1256 1264
48. Kielstein J. T., Beutel G., Fleig S., et al. Collaborators of the DGfN STEC-HUS registry. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant: 2012; 27 10 3807 3815
49. Ullrich S., Bremer P., Neumann-Grutzeck C., et al. Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study. PLoS ONE: 2013; 8 2 e55278
50. Romer S., Schaumburg F., Karch H., Schwindt W., Waltenberger J., Lebiedz P. Septic shock and ARDS after Eculizumab application in Shiga-toxin associated HUS during the outbreak of Shiga toxin-producing enterohaemorrhagic E. coli O104:H4. Med Klin: 2012; 107 4 329 330
51. Delmas Y., Vendrely B., Clouzeau B., et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant: 2014; 29 3 565 572
52. Harambat J., De Charette C., Godron A., Bordes C., Delmas Y., Llanas B. Eculizumab in Shiga toxin associated hemolytic uremic syndrome: a single center matched-cohort study. Pediatr Nephrol: 2013; 28 8 1373
53. Gitiaux C., Krug P., Grevent D., et al. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol: 2013; 55 8 758 765
54. Dhawan V., Ariyamuthu V., Malhotra K., Bichu P. Renal recovery in a child with D+HUS. Is eculizumab a typical drug? Am J Kidney Dis: 2013; 61 4 B37
55. Preuel K., Höhle M., Stark K., Werber D. Shiga toxin-producing Escherichia coli O157 is more likely to lead to hospitalization and death than non-O157 serogroups-except O104. PLoS ONE: 2013; 8 11 e78180
56. Thurman J. M., Marians R., Emlen W., et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol: 2009; 4 12 1920 1924
57. Morigi M., Galbusera M., Gastoldi S., et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol: 2011; 187 1 172 180
58. Rittirsch D., Redl H., Huber-Lang M. Role of complement in multiorgan failure. Clin Dev Immunol: 2012; 2012 962927
59. Würzner R., Orren A., Lachmann P. J. Inherited deficiencies of the terminal components of human complement. Immunodefic Rev: 1992; 3 2 123 147
60. Ricklin D., Lambris J. D. Complement-targeted therapeutics. Nat Biotechnol: 2007; 25 11 1265 1275
61. German Society of Nephrology Advice on the use of eculizumab during the 2011 EHEC HUS outbreak, 04.06.2011. Available at: http://www.dgfn.eu/fileadmin/ migrated/content-uploads/Advice-of-DGfN-on-the-use-of-eculizumab-in-EHEC-HUS- outbreak-20110604.pdf. Accessed April 29, 2014: 2011
62. Nitschke M., Sayk F., Härtel C., et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA: 2012; 307 10 1046 1052
63. Vonberg R. P., Höhle M., Aepfelbacher M., et al. Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. Clin Infect Dis: 2013; 56 8 1132 1140
64. Martin D. L., MacDonald K. L., White K. E., Soler J. T., Osterholm M. T. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med: 1990; 323 17 1161 1167